Mostrar el registro sencillo del ítem

dc.contributor.authorBlasco, María Teresa
dc.contributor.authorNavas, Carolina
dc.contributor.authorMartín-Serrano, Guillermo
dc.contributor.authorGraña Castro, Osvaldo 
dc.contributor.authorLechuga, Carmen G 
dc.contributor.authorMartín-Díaz, Laura
dc.contributor.authorDjurec, Magdolna
dc.contributor.authorLi, Jing
dc.contributor.authorMorales-Cacho, Lucia
dc.contributor.authorEsteban-Burgos, Laura 
dc.contributor.authorPerales-Patón, Javier
dc.contributor.authorBousquet-Mur, Emilie
dc.contributor.authorCastellano, Eva
dc.contributor.authorJacob, Harrys K C
dc.contributor.authorCabras, Lavinia
dc.contributor.authorMusteanu, Mónica 
dc.contributor.authorDrosten, Matthias 
dc.contributor.authorOrtega, Sagrario
dc.contributor.authorMulero, Francisca 
dc.contributor.authorSainz, Bruno
dc.contributor.authorDusetti, Nelson
dc.contributor.authorIovanna, Juan
dc.contributor.authorSanchez-Bueno, Francisco
dc.contributor.authorHidalgo, Manuel
dc.contributor.authorKhiabanian, Hossein
dc.contributor.authorRabadan, Raul
dc.contributor.authorAl-Shahrour, Fatima 
dc.contributor.authorGuerra, Carmen 
dc.contributor.authorBarbacid, Mariano 
dc.date.accessioned2019-08-21T09:13:18Z
dc.date.available2019-08-21T09:13:18Z
dc.date.issued2019-04-15
dc.identifier.citationCancer Cell. 2019;35(4):573-587.es_ES
dc.identifier.issn15356108es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/8310
dc.descriptionWe thank B. Jime ́nez, M. San Roman, R. Villar, and S. Jime ́nez for excellenttechnical assistance; I. Arago ́n, A. Lo ́pez, F. Dı ́az,and I. Blanco (Animal Facil-ity) for mouse work; G. Visdomine, C. Pen ̃alba, and G. Garaulet (MolecularImaging Unit) for ultrasound studies; P. Vargiu (Transgenic Unit) for help ingenerating theTetO-FlpOstrain; N. Cabrera, A. de Martino (HistopathologyUnit) and M. Morente (Tumor Bank) for histopathological analysis, andC. Blanco and A. Cebria ́(Experimental Therapeutics) for determining theIC50values of gefinitib and erlotinib. Special thanks to J. de la Pen ̃a and E. Ortiz(Servicio de Anatomı ́aPatolo ́gica HCUVA) and T. Escamez and V. Navarro(Biobanco-IMIM) for their help with the PDX tumor models, and to R. Nieto,J.M. Ligo ́s, and M. Montoya (Cytometry Unit, CNIC) for fluorescence-activatedcell sorting analysis of apoptotic cells. This work was supported by grants fromthe European Research Council (advanced grants ERC-AG/250297-RASAHEAD and ERC-AG/695566-THERACAN), from the Spanish Ministry ofEconomy and Competitiveness (SAF2014-59864-R) to M.B. Additional sup-port was also obtained from grants from the Asociacio ́n Espan ̃ola contra elCa ́ncer (GC16173694BARB) to M.B. and B.S., from La Ligue Contre le Cancerto J.I., from the European Research Council (advanced grants ERC-2014-ADG) to M.H., and from the NIH (U54CA193313 and U54CA209997) to R.R.M.T.B was supported by an FPU fellowship from the Spanish Ministry of Edu-cation. C.N. was supported by a Juan de la Cierva Award. M. Djurec waspartially supported by a pre-doctoral fellowship from La Caixa. J.P.-P. wassupported by a Severo Ochoa FPI fellowship from the Spanish Ministry ofEconomy and Competitiveness. M.B. is the recipient of an Endowed Chairfrom the AXA Research Fund.es_ES
dc.description.abstractFive-year survival for pancreatic ductal adenocarcinoma (PDAC) patients remains below 7% due to the lack of effective treatments. Here, we report that combined ablation of EGFR and c-RAF expression results in complete regression of a significant percentage of PDAC tumors driven by Kras/Trp53 mutations in genetically engineered mice. Moreover, systemic elimination of these targets induces toxicities that are well tolerated. Response to this targeted therapy correlates with transcriptional profiles that resemble those observed in human PDACs. Finally, inhibition of EGFR and c-RAF expression effectively blocked tumor progression in nine independent patient-derived xenografts carrying KRAS and TP53 mutations. These results open the door to the development of targeted therapies for PDAC patients.es_ES
dc.language.isoenges_ES
dc.publisherCell Press es_ES
dc.type.hasVersionSMURes_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/*
dc.subjectCdk4es_ES
dc.subjectEGFRes_ES
dc.subjectErlotinibes_ES
dc.subjectPDX tumor modelses_ES
dc.subjectPancreatic canceres_ES
dc.subjectc-Rafes_ES
dc.subjectTherapeutic mouse modelses_ES
dc.subjectTranscriptional profileses_ES
dc.subjectTumor regressiones_ES
dc.titleComplete Regression of Advanced Pancreatic Ductal Adenocarcinomas upon Combined Inhibition of EGFR and C-RAFes_ES
dc.typejournal articlees_ES
dc.rights.licenseAtribución-NoComercial-CompartirIgual 4.0 Internacional*
dc.identifier.pubmedID30975481es_ES
dc.format.volume35es_ES
dc.format.number4es_ES
dc.format.page573-587.e6es_ES
dc.identifier.doi10.1016/j.ccell.2019.03.002es_ES
dc.contributor.funderUnión Europea. Comisión Europea. European Research Council (ERC) 
dc.contributor.funderMinisterio de Economía y Competitividad (España) 
dc.contributor.funderAsociación Española Contra el Cáncer 
dc.contributor.funderLigue Nationale Contre le Cancer (Francia) 
dc.contributor.funderNIH - National Cancer Institute (NCI) (Estados Unidos) 
dc.contributor.funderFundación La Caixa 
dc.contributor.funderFundación AXA 
dc.description.peerreviewedSíes_ES
dc.identifier.e-issn1878-3686es_ES
dc.relation.publisherversionhttps://doi.org/10.1016/j.ccell.2019.03.002es_ES
dc.identifier.journalCancer celles_ES
dc.repisalud.institucionCNIOes_ES
dc.repisalud.orgCNIOCNIO::Grupos de investigación::Grupo de Oncología Experimentales_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/FP7/250297es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/H2020/695566es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/SAF2014-59864-Res_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/GC16173694BARBes_ES
dc.rights.accessRightsopen accesses_ES


Ficheros en el ítem

Acceso Abierto
Thumbnail
Nombre:
CompleteRegressionofAdvancedPa ...
Tamaño:
3.037Mb
Formato:
PDF
Visualizar/Abrir

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución-NoComercial-CompartirIgual 4.0 Internacional
Este Item está sujeto a una licencia Creative Commons: Atribución-NoComercial-CompartirIgual 4.0 Internacional